Marex Group’s TG Therapeutics TGTX Stock Holding History

Marex Group’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$15.2M	Sell	276,178 -2,165	-0.8%	-$88.6K	0.06%	159
2026 Q1	$9.25M	Sell	278,343 -8,287	-3%	-$247K	0.06%	164
2025 Q4	$8.54M	Sell	286,630 -7,828	-3%	-$256K	0.05%	168
2025 Q3	$10.6M	Buy	294,458 +16,142	+6%	+$532K	0.08%	142
2025 Q2	$10M	Buy	278,316 +3,316	+1%	+$123K	0.09%	134
2025 Q1	$10.8M	Hold	275,000	–	–	0.21%	67
2024 Q4	$8.28M	Hold	275,000	–	–	0.14%	76
2024 Q3	$6.43M	Hold	275,000	–	–	0.15%	85
2024 Q2	$4.89M	Hold	275,000	–	–	0.13%	97
2024 Q1	$4.18M	Hold	275,000	–	–	0.14%	102
2023 Q4	$4.7M	Buy	+275,000	New	+$3.2M	0.18%	102

Other funds holding TGTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Marex Group's TGTX Position: Q2 2026 in Review

Marex Group reduced its TG Therapeutics (TGTX) stake by 0.78% in Q2 2026, selling an estimated $88.6K and leaving 276,178 shares worth $15.2M. The position accounts for 0.06% of the portfolio, ranked #159.

Marex Group first reported a position in TGTX in Q4 2023 and has held it in 11 quarters since. 427 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

Marex Group held 276,178 shares of TG Therapeutics worth $15.2M as of Q2 2026.
Marex Group sold 2,165 TG Therapeutics shares in Q2 2026, an estimated $88.6K.
TG Therapeutics made up 0.06% of Marex Group's portfolio in Q2 2026, its #159 holding.
Marex Group first reported a position in TG Therapeutics in Q4 2023 and has held it in 11 quarters since.
427 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Marex Group's 13F filing for Q2 2026, filed 14 Aug 2026.